Your browser doesn't support javascript.
loading
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
Miyahira, Andrea K; Pienta, Kenneth J; Morris, Michael J; Bander, Neil H; Baum, Richard P; Fendler, Wolfgang P; Goeckeler, William; Gorin, Michael A; Hennekes, Hartwig; Pomper, Martin G; Sartor, Oliver; Tagawa, Scott T; Williams, Scott; Soule, Howard R.
  • Miyahira AK; Prostate Cancer Foundation, Santa Monica, California.
  • Pienta KJ; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Morris MJ; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bander NH; Weill Cornell Medicine, New York, New York.
  • Baum RP; THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.
  • Fendler WP; University of California, Los Angeles, California.
  • Goeckeler W; Bayer Healthcare, LLC, Whippany, New Jersey.
  • Gorin MA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Hennekes H; Bayer AG, Berlin, Germany.
  • Pomper MG; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Sartor O; Tulane University, New Orleans, Louisiana.
  • Tagawa ST; Weill Cornell Medicine, New York, New York.
  • Williams S; Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Soule HR; Prostate Cancer Foundation, Santa Monica, California.
Prostate ; 78(11): 775-789, 2018 08.
Article en En | MEDLINE | ID: mdl-29717499
ABSTRACT

INTRODUCTION:

The Prostate Cancer Foundation (PCF) convened a PSMA-Directed Radionuclide Scientific Working Group on November 14, 2017, at Weill Cornell Medicine, New York, NY.

METHODS:

The meeting was attended by 35 global investigators with expertise in prostate cancer biology, radionuclide therapy, molecular imaging, prostate-specific membrane antigen (PSMA)-targeted agents, drug development, and prostate cancer clinical trials. The goal of this meeting was to discuss the potential for using PSMA-targeted radionuclide agents for the treatment of advanced prostate cancer and to define the studies and clinical trials necessary for validating and optimizing the use of these agents.

RESULTS:

Several major topic areas were discussed including the overview of PSMA biology, lessons and applications of PSMA-targeted PET imaging, the nuances of designing PSMA-targeted radionuclide agents, clinical experiences with PSMA-targeted radionuclides, PCF-funded projects to accelerate PSMA-targeted radionuclide therapy, and barriers to the use of radionuclide treatments in widespread clinical practice.

DISCUSSION:

This article reviews the major topics discussed at the meeting with the goal of promoting research that will validate and optimize the use of PSMA-targeted radionuclide therapies for the treatment of advanced prostate cancer.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Radiofármacos / Glutamato Carboxipeptidasa II / Antígenos de Superficie Tipo de estudio: Clinical_trials Límite: Humans / Male Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Radiofármacos / Glutamato Carboxipeptidasa II / Antígenos de Superficie Tipo de estudio: Clinical_trials Límite: Humans / Male Idioma: En Año: 2018 Tipo del documento: Article